[go: up one dir, main page]

NI200700138A - Sal potasica de un inhibidor de la integrasa de vih - Google Patents

Sal potasica de un inhibidor de la integrasa de vih

Info

Publication number
NI200700138A
NI200700138A NI200700138A NI200700138A NI200700138A NI 200700138 A NI200700138 A NI 200700138A NI 200700138 A NI200700138 A NI 200700138A NI 200700138 A NI200700138 A NI 200700138A NI 200700138 A NI200700138 A NI 200700138A
Authority
NI
Nicaragua
Prior art keywords
inhibitor
hiv
integras
compound
potassic salt
Prior art date
Application number
NI200700138A
Other languages
English (en)
Inventor
Kevin M Belyk
Philip Jones
Henry G Morrison
Vincenzo Summa
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36171569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI200700138(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of NI200700138A publication Critical patent/NI200700138A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen sales potásicas del compuesto A y procedimientos para su preparación, en las que compuesto A es de la fórmula. El compuesto A es un inhibidor de la integrasa de VIH de utilidad para el tratamiento o la profilaxis de la infección por VIH, para retrasar el inicio del SIDA, y para el tratamiento o la profilaxis del SIDA.
NI200700138A 2004-12-03 2007-05-28 Sal potasica de un inhibidor de la integrasa de vih NI200700138A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63313204P 2004-12-03 2004-12-03

Publications (1)

Publication Number Publication Date
NI200700138A true NI200700138A (es) 2008-05-13

Family

ID=36171569

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200700138A NI200700138A (es) 2004-12-03 2007-05-28 Sal potasica de un inhibidor de la integrasa de vih

Country Status (35)

Country Link
US (2) US7754731B2 (es)
EP (2) EP1819700B1 (es)
JP (1) JP4705956B2 (es)
KR (2) KR20130122031A (es)
CN (1) CN101068793B (es)
AR (2) AR052034A1 (es)
AT (2) ATE518844T1 (es)
AU (1) AU2005311671B8 (es)
BR (1) BRPI0518760A8 (es)
CA (1) CA2588398C (es)
CR (1) CR9146A (es)
CY (1) CY1112859T1 (es)
DK (1) DK1819700T3 (es)
EA (1) EA012418B1 (es)
ES (2) ES2370136T3 (es)
GE (1) GEP20105086B (es)
HR (1) HRP20120066T1 (es)
IL (1) IL183614A (es)
MA (1) MA29120B1 (es)
ME (1) ME01985B (es)
MX (1) MX2007006639A (es)
MY (1) MY144320A (es)
NI (1) NI200700138A (es)
NO (1) NO338784B1 (es)
NZ (1) NZ555376A (es)
PE (1) PE20061148A1 (es)
PL (1) PL1819700T3 (es)
PT (1) PT1819700E (es)
RS (1) RS52197B (es)
SI (1) SI1819700T1 (es)
TN (1) TNSN07215A1 (es)
TW (1) TWI344463B (es)
UA (1) UA87884C2 (es)
WO (2) WO2006060730A2 (es)
ZA (1) ZA200704130B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1725528T3 (da) 2004-03-11 2013-09-02 4Sc Ag Sulfonylpyrroler som hdac-inhibitorer
JP2008521929A (ja) * 2004-12-03 2008-06-26 メルク エンド カムパニー インコーポレーテッド 抗核形成剤を含有する医薬組成物
RU2382648C2 (ru) * 2004-12-03 2010-02-27 Мерк Энд Ко., Инк. Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
CA2588466A1 (en) * 2004-12-03 2006-06-08 Merck & Co., Inc. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
BRPI0708470A2 (pt) * 2006-03-14 2011-05-31 Merck & Co Inc processo para a produção de partìculas cristalinas de um composto ativo orgánico, e, composição farmacêutica
AU2007275805A1 (en) 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: Inhibitors of HIV replication in combination therapy
US7687509B2 (en) 2007-07-09 2010-03-30 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives
JP5564435B2 (ja) * 2008-01-08 2014-07-30 メルク・シャープ・アンド・ドーム・コーポレーション Ｎ−置換ヒドロキシピリミジノンカルボキサミドの製造方法
ES2549387T3 (es) 2009-06-02 2015-10-27 Hetero Research Foundation Procedimiento de preparación de raltegravir potásico amorfo
WO2011024192A2 (en) 2009-07-27 2011-03-03 Matrix Laboratories Ltd Novel polymorphs of raltegravir
BR112012009857A8 (pt) 2009-10-26 2023-04-11 Merck Sharp & Dohme Composições farmacêuticas sólidas contendo um inibidor de integrase
DE102009056636A1 (de) 2009-12-02 2011-06-09 Ratiopharm Gmbh Raltegravir-Polymorphe
CN102753526B (zh) 2009-12-07 2014-11-26 佐治亚大学研究基金会 吡啶酮羟基环戊基羧酰胺：具有治疗用途的hiv 整合酶抑制剂
ES2362598B1 (es) * 2009-12-17 2012-06-13 Consejo Superior De Investigaciones Científicas (Csic) Uso del raltegravir y derivados para la elaboración de medicamentos destinados al tratamiento de infecciones por herpesvirus.
ES2524380T3 (es) 2010-04-01 2014-12-05 Teva Pharmaceutical Industries Ltd. Sales de raltegravir y formas cristalinas de las mismas
EP2552915B1 (en) * 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
EP2575465A4 (en) * 2010-05-25 2013-11-20 Hetero Research Foundation Raltegravir SALTS
WO2012009446A1 (en) 2010-07-16 2012-01-19 Concert Pharmaceuticals Inc. Novel pyrimidinecarboxamide derivatives
CN101914067B (zh) * 2010-08-26 2012-07-11 陈岱岭 N-甲基嘧啶酮的合成方法
JO3209B1 (ar) * 2010-11-05 2018-03-08 H Lundbeck As طريقة لتصنيع نالتريكسون
WO2012103105A1 (en) 2011-01-24 2012-08-02 Assia Chemical Industries Ltd. Processes for preparing raltegravir and intermediates in the processes
WO2012106534A2 (en) * 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
US9163009B2 (en) 2011-04-06 2015-10-20 Lupin Limited Salts of raltegravir
CA2833006A1 (en) * 2011-04-22 2012-10-26 Merck Sharp & Dohme Corp. Taste-masked formulations of raltegravir
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
EP2522665A1 (en) 2011-05-03 2012-11-14 Sandoz Ag Crystalline sodium salt of an HIV integrase inhibitor
ES2450944T3 (es) 2011-06-01 2014-03-25 Ratiopharm Gmbh Composición y comprimido que comprenden raltegravir
WO2013037731A1 (de) 2011-09-16 2013-03-21 Hexal Ag Neue polymorphe form von raltegravir-kalium
CN103130788B (zh) * 2011-11-24 2015-09-02 南开大学 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
CN103130787B (zh) * 2011-11-24 2015-06-10 南开大学 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
WO2013098854A2 (en) * 2011-12-26 2013-07-04 Emcure Pharmaceuticals Limited Synthesis of raltegravir
KR20140114406A (ko) 2012-01-25 2014-09-26 루핀 리미티드 안정한 비정질 랄테그라빌 포타슘 프리믹스 및 이의 제조 방법
WO2014064711A2 (en) * 2012-10-22 2014-05-01 Hetero Research Foundation Methods of administering raltegravir and raltegravir compositions
EP2818470A1 (en) 2013-06-27 2014-12-31 Basf Se Cocrystals of raltegravir potassium
WO2015009927A1 (en) * 2013-07-17 2015-01-22 Ratiopharm Gmbh Dolutegravir salts
CA2938387C (en) 2014-02-03 2021-03-02 Mylan Laboratories Ltd Processes for the preparation of intermediates of raltegravir
WO2015140765A1 (en) 2014-03-21 2015-09-24 Mylan Laboratories Ltd. A premix of crystalline raltegravir potassium salt and a process for the preparation thereof
US10257840B2 (en) 2014-10-22 2019-04-09 Telefonaktiebolaget Lm Ericsson (Publ) Operation of wireless local area network in the presence of periodic interference
US10259778B2 (en) 2014-11-10 2019-04-16 Aurobindo Pharma Ltd Process for the preparation of raltegravir
EP3472134B1 (en) * 2016-06-21 2021-10-20 Pharmathen S.A. Process for preparing compounds useful as intermediates for the preparation of raltegravir
EP3512854A1 (en) 2016-09-15 2019-07-24 Lupin Limited Process for the preparation of pure and stable crystalline raltegravir potassium form 3
CN108610338A (zh) * 2016-12-12 2018-10-02 天津国际生物医药联合研究院 一种嘧啶酮酰胺类化合物的制备方法
PL3710445T3 (pl) 2017-11-14 2022-06-20 Cambrex Profarmaco Milano S.R.L. Sposób wytwarzania raltegrawiru
WO2019236395A1 (en) * 2018-06-06 2019-12-12 Merck Sharp & Dohme Corp. Formulations of raltegravir
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
WO2021148992A1 (en) 2020-01-23 2021-07-29 Lupin Limited Pharmaceutical compositions of raltegravir

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624391A5 (es) * 1976-12-14 1981-07-31 Ciba Geigy Ag
US5717097A (en) 1991-11-08 1998-02-10 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL121789A (en) * 1996-10-03 2001-06-14 Rohm & Haas A medicinal product for inhibiting mammalian cell tumors
TR200101886T2 (tr) 1998-12-25 2001-12-21 Shionogi & Co., Ltd. HIV integrazını önleme aktivitesi olan aromatik heterosikl bileşimleri.
IT1318424B1 (it) 2000-03-24 2003-08-25 Unihart Corp Composti con attivita' anti-hiv.
HUP0302367A2 (hu) 2000-10-12 2003-11-28 Merck & Co., Inc. HIV Integráz inhibitorokként hasznos aza- és poliazanaftalenil-karboxamidok, ezeket tartalmazó gyógyszerkészítmények
GB0028483D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
UA77454C2 (en) * 2001-10-26 2006-12-15 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
AU2002357379A1 (en) 2001-12-21 2003-07-15 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
DE60329318D1 (de) 2002-11-20 2009-10-29 Japan Tobacco Inc 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
RU2329265C2 (ru) 2002-12-27 2008-07-20 Институто Ди Ричерке Ди Биолоджиа Молеколаре П.Анджелетти Спа ТЕТРАГИДРО-4Н-ПИРИДО[1,2-а]ПИРИМИДИНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ВИЧ-ИНТЕГРАЗЫ
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
RU2382648C2 (ru) * 2004-12-03 2010-02-27 Мерк Энд Ко., Инк. Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
JP2008521929A (ja) 2004-12-03 2008-06-26 メルク エンド カムパニー インコーポレーテッド 抗核形成剤を含有する医薬組成物
CA2588466A1 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1

Also Published As

Publication number Publication date
WO2006060712A2 (en) 2006-06-08
AU2005311671B8 (en) 2011-02-10
CA2588398A1 (en) 2006-06-08
AU2005311671A1 (en) 2006-06-08
MA29120B1 (fr) 2007-12-03
TW200631944A (en) 2006-09-16
EP1819683A2 (en) 2007-08-22
MX2007006639A (es) 2007-06-19
CR9146A (es) 2007-10-04
TNSN07215A1 (en) 2008-11-21
BRPI0518760A8 (pt) 2017-12-12
TWI344463B (en) 2011-07-01
KR101350420B1 (ko) 2014-02-17
JP4705956B2 (ja) 2011-06-22
NO338784B1 (no) 2016-10-17
BRPI0518760A2 (pt) 2008-12-09
RS52197B (sr) 2012-10-31
DK1819700T3 (da) 2012-03-19
EA200701204A1 (ru) 2007-12-28
PE20061148A1 (es) 2006-11-09
ATE518844T1 (de) 2011-08-15
SI1819700T1 (sl) 2012-07-31
KR20070089990A (ko) 2007-09-04
WO2006060730A2 (en) 2006-06-08
UA87884C2 (uk) 2009-08-25
AR052034A1 (es) 2007-02-28
CN101068793A (zh) 2007-11-07
PL1819700T3 (pl) 2012-04-30
EP1819700B1 (en) 2011-11-23
AU2005311671B2 (en) 2011-01-27
PT1819700E (pt) 2012-02-01
MY144320A (en) 2011-08-29
WO2006060712A3 (en) 2006-09-21
CY1112859T1 (el) 2016-04-13
WO2006060730A3 (en) 2006-08-17
EP1819700A2 (en) 2007-08-22
US20060122205A1 (en) 2006-06-08
ME01985B (me) 2012-10-31
JP2008521933A (ja) 2008-06-26
NZ555376A (en) 2009-11-27
WO2006060712A9 (en) 2006-07-27
US8357798B2 (en) 2013-01-22
HK1115011A1 (en) 2008-11-14
CN101068793B (zh) 2011-05-25
ATE534645T1 (de) 2011-12-15
IL183614A (en) 2012-03-29
NO20073404L (no) 2007-07-02
ZA200704130B (en) 2008-08-27
CA2588398C (en) 2011-07-12
IL183614A0 (en) 2007-09-20
ES2375788T3 (es) 2012-03-06
KR20130122031A (ko) 2013-11-06
US7754731B2 (en) 2010-07-13
ES2370136T3 (es) 2011-12-13
US20100249410A1 (en) 2010-09-30
AR101429A2 (es) 2016-12-21
GEP20105086B (en) 2010-10-11
EP1819683B1 (en) 2011-08-03
HRP20120066T1 (hr) 2012-03-31
EA012418B1 (ru) 2009-10-30

Similar Documents

Publication Publication Date Title
NI200700138A (es) Sal potasica de un inhibidor de la integrasa de vih
PE20130008A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
CO6331439A2 (es) 1-2 bicíclicos pirimidinona carboxamida como inhibidores de la integrasa del virus de inmunodeficiencia humana
DOP2016000265A (es) Inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4’
ECSP066826A (es) Inhibidores de integrasa de vih
CO6660497A2 (es) Derivados del ácido nft-2-ilacético para tratar el sida
EA202190473A3 (ru) Противовирусная терапия
EA201100994A1 (ru) Способ получения производных бисфуранового спирта, соединения, соль, фармацевтическая композиция на ее основе, способ лечения или профилактики ретровирусных инфекций с ее помощью
EA200401437A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы для лечения вич инфекции, способ их получения (варианты), способ увеличения периода полупревращения ненуклеозидного соединения, обладающего активностью против ретровирусов, и способ получения фармацевтической композиции, обладающей специфичностью к лейкоцитам
NI201200096A (es) Inhibidores de glucosilceramida sintasa
CR9694A (es) Inhibidores de la transcriptasa reversa de vih
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
CR20110184A (es) Inhibidores de la integrasa del vih
NO20090322L (no) 6-(heterosykel-substituert benzyl)-4-oksoquinolin forbindelse samt anvendelse av det samme som IIIV integrave inhibitor
GEP20207190B (en) Methods for treatment and prophylaxis of hiv and aids
CL2021001514A1 (es) Derivados de pirimidona como agentes citotóxicos selectivos contra células infectadas por vih.
CO2018007008A2 (es) "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo"
UY27809A1 (es) Inhibidores de la transcriptasa inversa no nucleosidos
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
AR077692A1 (es) Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
CL2008001537A1 (es) Compuestos heterociclo derivados de 1h-pirimidin-2,4-diona, dihidro-pirimidin-2,4-diona e imidazol-2,4-diona, inhibidores no nucleosidos de la transcriptasa inversa (nnrti) del vih-1; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por vih, sida o arc.
AR053345A1 (es) Compuesto de 1,2,4 triazolo-5-ona como inhibidores de la transcriptasa inversa
ATE380188T1 (de) Substituierte chinolone
DOP2005000244A (es) Sal potasica de un inhibidor de la integrasa del vih
MX2022011475A (es) Azd1656 para el uso en el tratamiento de neumonitis y/o la miocarditis causadas por un coronavirus.